These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 21903741

  • 1. Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study.
    Meng X, Loo BW, Ma L, Murphy JD, Sun X, Yu J.
    J Nucl Med; 2011 Oct; 52(10):1573-9. PubMed ID: 21903741
    [Abstract] [Full Text] [Related]

  • 2. Predictive efficacy of (11)C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity in non-small cell lung cancer patients.
    Dai D, Li XF, Wang J, Liu JJ, Zhu YJ, Zhang Y, Wang Q, Xu WG.
    Int J Cancer; 2016 Feb 15; 138(4):1003-12. PubMed ID: 26334931
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.
    Jpn J Clin Oncol; 2012 Jun 15; 42(6):528-33. PubMed ID: 22457323
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Assessment of simplified methods to measure 18F-FLT uptake changes in EGFR-mutated non-small cell lung cancer patients undergoing EGFR tyrosine kinase inhibitor treatment.
    Frings V, Yaqub M, Hoyng LL, Golla SS, Windhorst AD, Schuit RC, Lammertsma AA, Hoekstra OS, Smit EF, Boellaard R, QuIC-ConCePT Consortium.
    J Nucl Med; 2014 Sep 15; 55(9):1417-23. PubMed ID: 24970910
    [Abstract] [Full Text] [Related]

  • 8. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, Longchampt E, Wislez M, Coudert B, Daniel C, Chetaille B, Michiels S, Blons H, Solassol J, De Fraipont F, Foucher P, Urban T, Lacroix L, Poulot V, Quoix E, Antoine M, Danton G, Morin F, Chouaid C, Pignon JP.
    J Thorac Oncol; 2012 Oct 15; 7(10):1490-502. PubMed ID: 22982650
    [Abstract] [Full Text] [Related]

  • 9. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
    van Gool MH, Aukema TS, Schaake EE, Rijna H, Codrington HE, Valdés Olmos RA, Teertstra HJ, van Pel R, Burgers SA, van Tinteren H, Klomp HM.
    Ann Surg Oncol; 2014 Sep 15; 21(9):2831-7. PubMed ID: 24845729
    [Abstract] [Full Text] [Related]

  • 10. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
    Mileshkin L, Hicks RJ, Hughes BG, Mitchell PL, Charu V, Gitlitz BJ, Macfarlane D, Solomon B, Amler LC, Yu W, Pirzkall A, Fine BM.
    Clin Cancer Res; 2011 May 15; 17(10):3304-15. PubMed ID: 21364032
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D, Scheffler M, Zander T, Nogova L, Lammertsma AA, Boellaard R, Neumaier B, Ullrich RT, Holstein A, Dietlein M, Wolf J, Kobe C.
    J Nucl Med; 2011 Dec 15; 52(12):1871-7. PubMed ID: 22065872
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Timing of metabolic response monitoring during erlotinib treatment in non-small cell lung cancer.
    van Gool MH, Aukema TS, Schaake EE, Rijna H, Valdés Olmos RA, van Pel R, Burgers SA, van Tinteren H, Klomp HM, NEL Study Group.
    J Nucl Med; 2014 Jul 15; 55(7):1081-6. PubMed ID: 24812245
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. (18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib.
    Benz MR, Herrmann K, Walter F, Garon EB, Reckamp KL, Figlin R, Phelps ME, Weber WA, Czernin J, Allen-Auerbach MS.
    J Nucl Med; 2011 Nov 15; 52(11):1684-1689. PubMed ID: 22045706
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
    Tanaka K, Hata A, Kaji R, Fujita S, Otoshi T, Fujimoto D, Kawamura T, Tamai K, Takeshita J, Matsumoto T, Monden K, Nagata K, Otsuka K, Nakagawa A, Tachikawa R, Otsuka K, Tomii K, Katakami N.
    J Thorac Oncol; 2013 Jul 15; 8(7):892-8. PubMed ID: 23591159
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.